SurModics Expands Protein-Free Stabilizer Line with AP Option
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jul. 28, 2014--
SurModics IVD, Inc., a wholly owned subsidiary of SurModics, Inc.
(NASDAQ:SRDX) and a market leader for in
vitro diagnostic assay components, is introducing StabilZyme®
Protein-Free AP Stabilizer at the American Association for Clinical
Chemistry meeting currently taking place in Chicago.
“Protein interference is a frequent concern, particularly as more
sensitive assays are developed,” says Drew Pauly, Director of Product
Development, SurModics IVD. “Proteins used in many stabilizers can lead
to increased non-specific binding due to protein interference. There is
a need for a protein-free stabilizer for alkaline phosphatase conjugates
that delivers equivalent performance to protein-containing stabilizers,
including those with BSA (bovine serum albumin). This new StabilZyme
protein-free stabilizer achieves that goal.”
The new stabilizer eliminates protein-related interference and
cross-reactivity. It also offers excellent performance. The retained
activity of StabilZyme Protein-Free AP Stabilizer is comparable to its
protein-containing counterpart—StabilZyme AP Conjugate Stabilizer—and
superior to other protein-free/BSA-free stabilizers on the market. It
performs across all species of antibodies, even at low concentrations.
AACC attendees can learn more by visiting the SurModics IVD Booth #1938.
AACC is the world’s largest laboratory medicine exposition, with 20,000
SurModics IVD offers a full range of innovative solutions, including
custom formulations, for the in vitro diagnostics industry. To
learn more, visit our website (www.surmodics.com/ivd),
or contact customer service (952-500-7200 or firstname.lastname@example.org).
More than 900 IVD products are available for online ordering at shop.surmodics.com.
About SurModics, Inc.
SurModics' mission is to exceed our
customers' expectations and enhance the wellbeing of patients by
providing the world's foremost, innovative surface modification
technologies and in vitro diagnostic chemical components. The
Company partners with the world's leading and emerging medical device,
diagnostic and life science companies to develop and commercialize
innovative products designed to improve patient diagnosis and treatment.
Core offerings include (i) surface modification coating technologies
that impart lubricity, prohealing, and biocompatibility capabilities,
and (ii) components for in vitro diagnostic tests and
microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For
more information about the Company, visit http://www.surmodics.com.
The content of SurModics' website is not part of this release or part of
any filings the Company makes with the SEC.
SurModics and StabilZyme are registered trademarks of
SurModics, Inc. and/or its affiliates.
Source: SurModics, Inc.
Andy LaFrence, 952-500-7000
President Finance and Chief Financial Officer